Jounce Therapeutics, Inc. (JNCE) Declines Again; Strong Momentum for Sellers

May 17, 2018 - By Margaret Downey

The stock of Jounce Therapeutics, Inc. (NASDAQ:JNCE) is a huge mover today! The stock decreased 35.20% or $6.22 during the last trading session, reaching $11.45. About 6.87 million shares traded or 1705.63% up from the average. Jounce Therapeutics, Inc. (NASDAQ:JNCE) has declined 9.84% since May 18, 2017 and is downtrending. It has underperformed by 21.39% the S&P500.
The move comes after 9 months negative chart setup for the $371.94 million company. It was reported on May, 18 by Barchart.com. We have $10.42 PT which if reached, will make NASDAQ:JNCE worth $33.47M less.

Analysts await Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings on August, 8. They expect $-0.38 EPS, down 245.45 % or $0.27 from last year’s $-0.11 per share. After $-0.40 actual EPS reported by Jounce Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -5.00 % EPS growth.

More notable recent Jounce Therapeutics, Inc. (NASDAQ:JNCE) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More” on May 17, 2018, also Nasdaq.com with their article: “Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical …” published on May 16, 2018, Seekingalpha.com published: “Jounce Therapeutics’ (JNCE) CEO Rich Murray on Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. More interesting news about Jounce Therapeutics, Inc. (NASDAQ:JNCE) were released by: Benzinga.com and their article: “22 Stocks Moving In Thursday’s Pre-Market Session” published on May 17, 2018 as well as 247Wallst.com‘s news article titled: “Why Jounce Shares Are Crumbling Ahead of ASCO” with publication date: May 17, 2018.

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, focuses on developing therapies that enable the immune system to attack tumors. The company has market cap of $371.94 million. The Company’s lead product candidate, JTX-2011, is a clinical stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in various solid tumors. It currently has negative earnings. The firm is also developing JTX-4014, an anti-PD-1 antibody.

Jounce Therapeutics, Inc. (NASDAQ:JNCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: